| 1 | none | 8,646 |
| 2 | handsearches | 132 |
| 3 | sect | 23 |
| 4 | 8l | 15 |
| 5 | microfractures | 9 |
| 6 | 'frequency | 7 |
| 7 | smgs | 7 |
| 8 | b26arg | 6 |
| 9 | encyclopaedia | 6 |
| 10 | mrna-expression | 6 |
| 11 | com456 | 5 |
| 12 | ipt-wg | 5 |
| 13 | mp688 | 5 |
| 14 | 3-dag | 4 |
| 15 | 4g/d | 4 |
| 16 | cf-htc | 4 |
| 17 | dc-stimulation | 4 |
| 18 | decementation | 4 |
| 19 | dermatochalasis | 4 |
| 20 | destot | 4 |
| 21 | divorce/separation | 4 |
| 22 | fcj/fcpj | 4 |
| 23 | fenobucarb | 4 |
| 24 | immunodepletion | 4 |
| 25 | medialisation | 4 |
| 26 | microaspirations | 4 |
| 27 | minimalization | 4 |
| 28 | mismeasurement | 4 |
| 29 | monoadministration | 4 |
| 30 | nos-dependence | 4 |
| 31 | silver-coating | 4 |
| 32 | sss2a | 4 |
| 33 | web/mail | 4 |
| 34 | 'attitude | 3 |
| 35 | 1+/-2 | 3 |
| 36 | 40g | 3 |
| 37 | 4169 | 3 |
| 38 | cellonex™ | 3 |
| 39 | co-deletion | 3 |
| 40 | coimmunoprecipitations | 3 |
| 41 | cross-transferability | 3 |
| 42 | dna-test | 3 |
| 43 | emperors | 3 |
| 44 | ets-exposure | 3 |
| 45 | gemifloxacin/azithromycin | 3 |
| 46 | hal2pim | 3 |
| 47 | l-placebo | 3 |
| 48 | macrodontia | 3 |
| 49 | marop1 | 3 |
| 50 | measure/s | 3 |
| 51 | mock-ups | 3 |
| 52 | monozygosity | 3 |
| 53 | ngmi | 3 |
| 54 | non-consideration | 3 |
| 55 | non-culturable | 3 |
| 56 | non-support | 3 |
| 57 | papillitis | 3 |
| 58 | pyes2.0 | 3 |
| 59 | rbc-aa | 3 |
| 60 | re-supply | 3 |
| 61 | re-suspension | 3 |
| 62 | reduction/suppression | 3 |
| 63 | sacculations | 3 |
| 64 | submariners | 3 |
| 65 | ual/sal | 3 |
| 66 | uncleanliness | 3 |
| 67 | under-users | 3 |
| 68 | 'edema | 2 |
| 69 | 'effects | 2 |
| 70 | 'identification | 2 |
| 71 | 'regulation | 2 |
| 72 | 'science | 2 |
| 73 | 'sources | 2 |
| 74 | 109.7° | 2 |
| 75 | 11,967 | 2 |
| 76 | 1500mg/kg | 2 |
| 77 | 19/49 | 2 |
| 78 | 27,062 | 2 |
| 79 | 3-egfps | 2 |
| 80 | 35/54 | 2 |
| 81 | 3549 | 2 |
| 82 | 4g/l | 2 |
| 83 | 6g/100g | 2 |
| 84 | 80g | 2 |
| 85 | adultery | 2 |
| 86 | aminomethylation | 2 |
| 87 | anisonucleosis | 2 |
| 88 | anti-cd14 | 2 |
| 89 | axos-breads | 2 |
| 90 | b*44:27 | 2 |
| 91 | bioevaluation | 2 |
| 92 | biogenesis/assembly | 2 |
| 93 | c-terminal-telopeptides | 2 |
| 94 | carboxy-telopeptide | 2 |
| 95 | chronization | 2 |
| 96 | co-dosing | 2 |
| 97 | co-inoculation | 2 |
| 98 | eb172 | 2 |
| 99 | ema/pma-qpcr | 2 |
| 100 | f-scores | 2 |
| 101 | fractioning | 2 |
| 102 | functionalizations | 2 |
| 103 | immunoprobing | 2 |
| 104 | insulinization | 2 |
| 105 | leatherbacks | 2 |
| 106 | meddiet-wl | 2 |
| 107 | metorrhagia | 2 |
| 108 | morpho-anatomy | 2 |
| 109 | multiparticulates | 2 |
| 110 | n4-nymphs | 2 |
| 111 | non-receipt | 2 |
| 112 | nonengagement | 2 |
| 113 | nonplacement | 2 |
| 114 | nonstandardization | 2 |
| 115 | osypka-electrodes | 2 |
| 116 | over-absorption | 2 |
| 117 | pan-inhibition | 2 |
| 118 | pentalogy | 2 |
| 119 | photocopies | 2 |
| 120 | pinches | 2 |
| 121 | placebo-dp | 2 |
| 122 | placentomas | 2 |
| 123 | plain-radiography | 2 |
| 124 | practicians | 2 |
| 125 | pre-infusions | 2 |
| 126 | prelicensing | 2 |
| 127 | pseudo-tumour | 2 |
| 128 | remaking | 2 |
| 129 | resensitization | 2 |
| 130 | rhi+rhuph20 | 2 |
| 131 | riv/bullock | 2 |
| 132 | s'lateral | 2 |
| 133 | six1 | 2 |
| 134 | sixty-percent | 2 |
| 135 | solarization | 2 |
| 136 | start-strengths | 2 |
| 137 | sucking-tucking | 2 |
| 138 | tadenan | 2 |
| 139 | teacorac | 2 |
| 140 | theaim | 2 |
| 141 | time-to-use | 2 |
| 142 | toxigenesis | 2 |
| 143 | underinflation | 2 |
| 144 | wcg3 | 2 |
| 145 | 'aggregation | 1 |
| 146 | 'impacts | 1 |
| 147 | 'initiation | 1 |
| 148 | 'legitimacy | 1 |
| 149 | 'rigour | 1 |
| 150 | 'sincerity | 1 |
| 151 | -outcomes | 1 |
| 152 | 0.12±0.003ml/kg | 1 |
| 153 | 0.14/subject/month | 1 |
| 154 | 0.44.fluoxetine | 1 |
| 155 | 0.48±0.02g | 1 |
| 156 | 0=absence | 1 |
| 157 | 1-oh | 1 |
| 158 | 1/5-1/4 | 1 |
| 159 | 10+/-2.41 | 1 |
| 160 | 10,356 | 1 |
| 161 | 10-50μg/kg | 1 |
| 162 | 1086-1087 | 1 |
| 163 | 11/154 | 1 |
| 164 | 13,489 | 1 |
| 165 | 1313±603 | 1 |
| 166 | 15x | 1 |
| 167 | 16b | 1 |
| 168 | 17+/-7.93 | 1 |
| 169 | 17,779 | 1 |
| 170 | 179,149 | 1 |
| 171 | 18+/-1.32 | 1 |
| 172 | 180,894 | 1 |
| 173 | 1965.-spores | 1 |
| 174 | 1=presence | 1 |
| 175 | 2,3,7,8-tetrabromo-dibenzodioxin | 1 |
| 176 | 20.3g/kg | 1 |
| 177 | 2005-31 | 1 |
| 178 | 210.g | 1 |
| 179 | 22,6±3,6 | 1 |
| 180 | 26,601 | 1 |
| 181 | 28,156 | 1 |
| 182 | 28,661 | 1 |
| 183 | 2=presence | 1 |
| 184 | 3.00dc | 1 |
| 185 | 3.54-/+1.95 | 1 |
| 186 | 30,495 | 1 |
| 187 | 38µg/kg | 1 |
| 188 | 3d-ctc | 1 |
| 189 | 4,513 | 1 |
| 190 | 4-hour-area-under-the-curve | 1 |
| 191 | 44mg | 1 |
| 192 | 577/1500 | 1 |
| 193 | 5783 | 1 |
| 194 | 59±11g | 1 |
| 195 | 6,248 | 1 |
| 196 | 62/113 | 1 |
| 197 | 6337 | 1 |
| 198 | 63·0 | 1 |
| 199 | 7,97±1,87 | 1 |
| 200 | 7.5tymg | 1 |
| 201 | 72/93 | 1 |
| 202 | 75-couples | 1 |
| 203 | 90+/-0.71 | 1 |
| 204 | 90+/-1.86 | 1 |
| 205 | 90,517 | 1 |
| 206 | accuracy/specificity | 1 |
| 207 | administra-tion | 1 |
| 208 | agroinoculation | 1 |
| 209 | alpha-factor | 1 |
| 210 | altars | 1 |
| 211 | angioscan | 1 |
| 212 | antibodies-to-golimumab | 1 |
| 213 | asynchronization | 1 |
| 214 | availablility | 1 |
| 215 | barrier-type | 1 |
| 216 | behavior/out | 1 |
| 217 | benzoannulation | 1 |
| 218 | beta-ol-15-one | 1 |
| 219 | bi-transplantation | 1 |
| 220 | bio-compatibility | 1 |
| 221 | bioavalability | 1 |
| 222 | bleeding/bruising | 1 |
| 223 | boxplots | 1 |
| 224 | c21min | 1 |
| 225 | cases-folders | 1 |
| 226 | catecholamine-regulation | 1 |
| 227 | chemo-degradation | 1 |
| 228 | chemomodulation | 1 |
| 229 | chest-ct-scans | 1 |
| 230 | chondosarcoma | 1 |
| 231 | ciii2/cii | 1 |
| 232 | co-blockade | 1 |
| 233 | co-deficiency | 1 |
| 234 | co-immunprecipitation | 1 |
| 235 | co-provision | 1 |
| 236 | co-targeting | 1 |
| 237 | comparism | 1 |
| 238 | consecration | 1 |
| 239 | context-studies | 1 |
| 240 | cooverexpression | 1 |
| 241 | cytoviability | 1 |
| 242 | day-wetting | 1 |
| 243 | de-regulation | 1 |
| 244 | degloving | 1 |
| 245 | demages | 1 |
| 246 | devitalisation | 1 |
| 247 | devoided | 1 |
| 248 | diarrrhoea | 1 |
| 249 | differentiation/polarization | 1 |
| 250 | disappearence | 1 |
| 251 | disfluently | 1 |
| 252 | dp-gram | 1 |
| 253 | drug-prevention | 1 |
| 254 | drugability | 1 |
| 255 | effectivization | 1 |
| 256 | eighty-percent | 1 |
| 257 | electro-activation | 1 |
| 258 | electro-polymerisation | 1 |
| 259 | eruption/noneruption | 1 |
| 260 | erβ-positive | 1 |
| 261 | establisment | 1 |
| 262 | exfusion | 1 |
| 263 | fdaes | 1 |
| 264 | feasibilty | 1 |
| 265 | flowerbud | 1 |
| 266 | follow-op | 1 |
| 267 | g4-mixture | 1 |
| 268 | gal/wilcock | 1 |
| 269 | gamma-family | 1 |
| 270 | glu100 | 1 |
| 271 | gsos | 1 |
| 272 | guesstimates | 1 |
| 273 | h272a | 1 |
| 274 | hdl-lipoproteins | 1 |
| 275 | hemi-ablation | 1 |
| 276 | hepaticogastrotomy | 1 |
| 277 | homomutants | 1 |
| 278 | hongbaozhai | 1 |
| 279 | humanisation | 1 |
| 280 | hyperamylaesemia | 1 |
| 281 | il-6-stimulation | 1 |
| 282 | imatinib-600mg | 1 |
| 283 | immunocharacteristics | 1 |
| 284 | immunodensity | 1 |
| 285 | immunolocalizations | 1 |
| 286 | impairmant | 1 |
| 287 | implanatation | 1 |
| 288 | imunoblotting | 1 |
| 289 | insufficient/lack | 1 |
| 290 | invastigation | 1 |
| 291 | its-rflp | 1 |
| 292 | judicialization | 1 |
| 293 | k256a | 1 |
| 294 | lab-demineralization | 1 |
| 295 | laboratory-confirmation | 1 |
| 296 | legitimatization | 1 |
| 297 | lipid-formulations | 1 |
| 298 | lnterventions | 1 |
| 299 | long-term-effects | 1 |
| 300 | lys890 | 1 |
| 301 | maidens | 1 |
| 302 | maintenance/increase | 1 |
| 303 | marriageability | 1 |
| 304 | maternal-to-child-transmission | 1 |
| 305 | mcrs | 1 |
| 306 | meausured | 1 |
| 307 | mecanism | 1 |
| 308 | met-159 | 1 |
| 309 | methylation-silencing | 1 |
| 310 | mic50/mic90 | 1 |
| 311 | microdensitometry | 1 |
| 312 | mini-dosage | 1 |
| 313 | mis-recording | 1 |
| 314 | mistnetting | 1 |
| 315 | mono-n-arylation | 1 |
| 316 | mono-pegylation | 1 |
| 317 | multistageness | 1 |
| 318 | n-terminal-prohormone | 1 |
| 319 | n6-derivatives | 1 |
| 320 | nanoheterostructures/mixtures | 1 |
| 321 | nanolizing | 1 |
| 322 | nhe3-s515d | 1 |
| 323 | nighty-eight | 1 |
| 324 | nine-month-olds | 1 |
| 325 | non-neutropenia | 1 |
| 326 | non-observances | 1 |
| 327 | non-recommendation | 1 |
| 328 | noncoresidentiality | 1 |
| 329 | nonfsws | 1 |
| 330 | nonoverlap | 1 |
| 331 | observer-rating | 1 |
| 332 | occurrence/duration | 1 |
| 333 | over-repetition | 1 |
| 334 | over-stretching | 1 |
| 335 | parent/s | 1 |
| 336 | pc-coating | 1 |
| 337 | percpetions | 1 |
| 338 | peritonitiss | 1 |
| 339 | pharmacoprevention | 1 |
| 340 | phosphomimics | 1 |
| 341 | physician-assessment | 1 |
| 342 | pif4-dependency | 1 |
| 343 | police-records | 1 |
| 344 | polysomnographs | 1 |
| 345 | portents | 1 |
| 346 | post-analysis | 1 |
| 347 | pre-addition | 1 |
| 348 | pre-metalation | 1 |
| 349 | predictors/correlates | 1 |
| 350 | preinhibition | 1 |
| 351 | prevention-by-detection | 1 |
| 352 | protocolization | 1 |
| 353 | pseudo-subluxation | 1 |
| 354 | pumping.initiation | 1 |
| 355 | purpouse | 1 |
| 356 | qanun | 1 |
| 357 | radiometabolites | 1 |
| 358 | radiomethylation | 1 |
| 359 | ranges-of-motion | 1 |
| 360 | re-supplementation | 1 |
| 361 | re-ulcerations | 1 |
| 362 | reactogenicities | 1 |
| 363 | recondensation | 1 |
| 364 | results-27,495 | 1 |
| 365 | results.-forty-one | 1 |
| 366 | ricochet | 1 |
| 367 | rnai-knockdown | 1 |
| 368 | robustification | 1 |
| 369 | rs1544210 | 1 |
| 370 | rupture/dissection | 1 |
| 371 | sdspage | 1 |
| 372 | self-predictions | 1 |
| 373 | semiquantitation | 1 |
| 374 | serials | 1 |
| 375 | seroprevalency | 1 |
| 376 | seventy-fife | 1 |
| 377 | sigma/epsilon | 1 |
| 378 | staurosporine/h89-sensitive | 1 |
| 379 | subphenotyping | 1 |
| 380 | subspecialisation | 1 |
| 381 | subterms | 1 |
| 382 | suzuki-coupling | 1 |
| 383 | t1-effects | 1 |
| 384 | t1-ld | 1 |
| 385 | t1=start | 1 |
| 386 | t2-ld | 1 |
| 387 | t3-ld | 1 |
| 388 | tamaris | 1 |
| 389 | tape-recordings | 1 |
| 390 | tc-99m-hdp-spect/ct | 1 |
| 391 | ten-year-risk | 1 |
| 392 | thearomaticities | 1 |
| 393 | theconcentrations | 1 |
| 394 | thermal-activation | 1 |
| 395 | thermo-acclimated | 1 |
| 396 | thermoactivity | 1 |
| 397 | theuse | 1 |
| 398 | times-series | 1 |
| 399 | tnf-α-modulation | 1 |
| 400 | trans-stimulation | 1 |
| 401 | transcomplementation | 1 |
| 402 | transplantation/infusion | 1 |
| 403 | treatment-effects | 1 |
| 404 | triplots | 1 |
| 405 | trofozoites | 1 |
| 406 | twenty-items | 1 |
| 407 | type/side | 1 |
| 408 | uninducibility | 1 |
| 409 | unkindled | 1 |
| 410 | unplanned-use | 1 |
| 411 | wb-mris | 1 |
| 412 | withdrawel | 1 |
| 413 | x-ray-dose | 1 |
| 414 | ~bullet~withdrawal | 1 |
| 415 | «history | 1 |
| 416 | β-cleavage | 1 |
| 417 | β1-subunit | 1 |
| 418 | ιmmunoreactivity | 1 |
| 419 | •discrimination | 1 |
| 420 | •harms | 1 |
| 421 | •meta-analysis | 1 |
| 422 | •predictors | 1 |
| 423 | ≥20/400 | 1 |
| 1 | 'aggregation | 1 |
| 2 | 'attitude | 3 |
| 3 | 'edema | 2 |
| 4 | 'effects | 2 |
| 5 | 'frequency | 7 |
| 6 | 'identification | 2 |
| 7 | 'impacts | 1 |
| 8 | 'initiation | 1 |
| 9 | 'legitimacy | 1 |
| 10 | 'regulation | 2 |
| 11 | 'rigour | 1 |
| 12 | 'science | 2 |
| 13 | 'sincerity | 1 |
| 14 | 'sources | 2 |
| 15 | -outcomes | 1 |
| 16 | 0.12±0.003ml/kg | 1 |
| 17 | 0.14/subject/month | 1 |
| 18 | 0.44.fluoxetine | 1 |
| 19 | 0.48±0.02g | 1 |
| 20 | 0=absence | 1 |
| 21 | 1+/-2 | 3 |
| 22 | 1-oh | 1 |
| 23 | 1/5-1/4 | 1 |
| 24 | 10+/-2.41 | 1 |
| 25 | 10,356 | 1 |
| 26 | 10-50μg/kg | 1 |
| 27 | 1086-1087 | 1 |
| 28 | 109.7° | 2 |
| 29 | 11,967 | 2 |
| 30 | 11/154 | 1 |
| 31 | 13,489 | 1 |
| 32 | 1313±603 | 1 |
| 33 | 1500mg/kg | 2 |
| 34 | 15x | 1 |
| 35 | 16b | 1 |
| 36 | 17+/-7.93 | 1 |
| 37 | 17,779 | 1 |
| 38 | 179,149 | 1 |
| 39 | 18+/-1.32 | 1 |
| 40 | 180,894 | 1 |
| 41 | 19/49 | 2 |
| 42 | 1965.-spores | 1 |
| 43 | 1=presence | 1 |
| 44 | 2,3,7,8-tetrabromo-dibenzodioxin | 1 |
| 45 | 20.3g/kg | 1 |
| 46 | 2005-31 | 1 |
| 47 | 210.g | 1 |
| 48 | 22,6±3,6 | 1 |
| 49 | 26,601 | 1 |
| 50 | 27,062 | 2 |
| 51 | 28,156 | 1 |
| 52 | 28,661 | 1 |
| 53 | 2=presence | 1 |
| 54 | 3-dag | 4 |
| 55 | 3-egfps | 2 |
| 56 | 3.00dc | 1 |
| 57 | 3.54-/+1.95 | 1 |
| 58 | 30,495 | 1 |
| 59 | 35/54 | 2 |
| 60 | 3549 | 2 |
| 61 | 38µg/kg | 1 |
| 62 | 3d-ctc | 1 |
| 63 | 4,513 | 1 |
| 64 | 4-hour-area-under-the-curve | 1 |
| 65 | 40g | 3 |
| 66 | 4169 | 3 |
| 67 | 44mg | 1 |
| 68 | 4g/d | 4 |
| 69 | 4g/l | 2 |
| 70 | 577/1500 | 1 |
| 71 | 5783 | 1 |
| 72 | 59±11g | 1 |
| 73 | 6,248 | 1 |
| 74 | 62/113 | 1 |
| 75 | 6337 | 1 |
| 76 | 63·0 | 1 |
| 77 | 6g/100g | 2 |
| 78 | 7,97±1,87 | 1 |
| 79 | 7.5tymg | 1 |
| 80 | 72/93 | 1 |
| 81 | 75-couples | 1 |
| 82 | 80g | 2 |
| 83 | 8l | 15 |
| 84 | 90+/-0.71 | 1 |
| 85 | 90+/-1.86 | 1 |
| 86 | 90,517 | 1 |
| 87 | accuracy/specificity | 1 |
| 88 | administra-tion | 1 |
| 89 | adultery | 2 |
| 90 | agroinoculation | 1 |
| 91 | alpha-factor | 1 |
| 92 | altars | 1 |
| 93 | aminomethylation | 2 |
| 94 | angioscan | 1 |
| 95 | anisonucleosis | 2 |
| 96 | anti-cd14 | 2 |
| 97 | antibodies-to-golimumab | 1 |
| 98 | asynchronization | 1 |
| 99 | availablility | 1 |
| 100 | axos-breads | 2 |
| 101 | b*44:27 | 2 |
| 102 | b26arg | 6 |
| 103 | barrier-type | 1 |
| 104 | behavior/out | 1 |
| 105 | benzoannulation | 1 |
| 106 | beta-ol-15-one | 1 |
| 107 | bi-transplantation | 1 |
| 108 | bio-compatibility | 1 |
| 109 | bioavalability | 1 |
| 110 | bioevaluation | 2 |
| 111 | biogenesis/assembly | 2 |
| 112 | bleeding/bruising | 1 |
| 113 | boxplots | 1 |
| 114 | c-terminal-telopeptides | 2 |
| 115 | c21min | 1 |
| 116 | carboxy-telopeptide | 2 |
| 117 | cases-folders | 1 |
| 118 | catecholamine-regulation | 1 |
| 119 | cellonex™ | 3 |
| 120 | cf-htc | 4 |
| 121 | chemo-degradation | 1 |
| 122 | chemomodulation | 1 |
| 123 | chest-ct-scans | 1 |
| 124 | chondosarcoma | 1 |
| 125 | chronization | 2 |
| 126 | ciii2/cii | 1 |
| 127 | co-blockade | 1 |
| 128 | co-deficiency | 1 |
| 129 | co-deletion | 3 |
| 130 | co-dosing | 2 |
| 131 | co-immunprecipitation | 1 |
| 132 | co-inoculation | 2 |
| 133 | co-provision | 1 |
| 134 | co-targeting | 1 |
| 135 | coimmunoprecipitations | 3 |
| 136 | com456 | 5 |
| 137 | comparism | 1 |
| 138 | consecration | 1 |
| 139 | context-studies | 1 |
| 140 | cooverexpression | 1 |
| 141 | cross-transferability | 3 |
| 142 | cytoviability | 1 |
| 143 | day-wetting | 1 |
| 144 | dc-stimulation | 4 |
| 145 | de-regulation | 1 |
| 146 | decementation | 4 |
| 147 | degloving | 1 |
| 148 | demages | 1 |
| 149 | dermatochalasis | 4 |
| 150 | destot | 4 |
| 151 | devitalisation | 1 |
| 152 | devoided | 1 |
| 153 | diarrrhoea | 1 |
| 154 | differentiation/polarization | 1 |
| 155 | disappearence | 1 |
| 156 | disfluently | 1 |
| 157 | divorce/separation | 4 |
| 158 | dna-test | 3 |
| 159 | dp-gram | 1 |
| 160 | drug-prevention | 1 |
| 161 | drugability | 1 |
| 162 | eb172 | 2 |
| 163 | effectivization | 1 |
| 164 | eighty-percent | 1 |
| 165 | electro-activation | 1 |
| 166 | electro-polymerisation | 1 |
| 167 | ema/pma-qpcr | 2 |
| 168 | emperors | 3 |
| 169 | encyclopaedia | 6 |
| 170 | eruption/noneruption | 1 |
| 171 | erβ-positive | 1 |
| 172 | establisment | 1 |
| 173 | ets-exposure | 3 |
| 174 | exfusion | 1 |
| 175 | f-scores | 2 |
| 176 | fcj/fcpj | 4 |
| 177 | fdaes | 1 |
| 178 | feasibilty | 1 |
| 179 | fenobucarb | 4 |
| 180 | flowerbud | 1 |
| 181 | follow-op | 1 |
| 182 | fractioning | 2 |
| 183 | functionalizations | 2 |
| 184 | g4-mixture | 1 |
| 185 | gal/wilcock | 1 |
| 186 | gamma-family | 1 |
| 187 | gemifloxacin/azithromycin | 3 |
| 188 | glu100 | 1 |
| 189 | gsos | 1 |
| 190 | guesstimates | 1 |
| 191 | h272a | 1 |
| 192 | hal2pim | 3 |
| 193 | handsearches | 132 |
| 194 | hdl-lipoproteins | 1 |
| 195 | hemi-ablation | 1 |
| 196 | hepaticogastrotomy | 1 |
| 197 | homomutants | 1 |
| 198 | hongbaozhai | 1 |
| 199 | humanisation | 1 |
| 200 | hyperamylaesemia | 1 |
| 201 | il-6-stimulation | 1 |
| 202 | imatinib-600mg | 1 |
| 203 | immunocharacteristics | 1 |
| 204 | immunodensity | 1 |
| 205 | immunodepletion | 4 |
| 206 | immunolocalizations | 1 |
| 207 | immunoprobing | 2 |
| 208 | impairmant | 1 |
| 209 | implanatation | 1 |
| 210 | imunoblotting | 1 |
| 211 | insufficient/lack | 1 |
| 212 | insulinization | 2 |
| 213 | invastigation | 1 |
| 214 | ipt-wg | 5 |
| 215 | its-rflp | 1 |
| 216 | judicialization | 1 |
| 217 | k256a | 1 |
| 218 | l-placebo | 3 |
| 219 | lab-demineralization | 1 |
| 220 | laboratory-confirmation | 1 |
| 221 | leatherbacks | 2 |
| 222 | legitimatization | 1 |
| 223 | lipid-formulations | 1 |
| 224 | lnterventions | 1 |
| 225 | long-term-effects | 1 |
| 226 | lys890 | 1 |
| 227 | macrodontia | 3 |
| 228 | maidens | 1 |
| 229 | maintenance/increase | 1 |
| 230 | marop1 | 3 |
| 231 | marriageability | 1 |
| 232 | maternal-to-child-transmission | 1 |
| 233 | mcrs | 1 |
| 234 | measure/s | 3 |
| 235 | meausured | 1 |
| 236 | mecanism | 1 |
| 237 | meddiet-wl | 2 |
| 238 | medialisation | 4 |
| 239 | met-159 | 1 |
| 240 | methylation-silencing | 1 |
| 241 | metorrhagia | 2 |
| 242 | mic50/mic90 | 1 |
| 243 | microaspirations | 4 |
| 244 | microdensitometry | 1 |
| 245 | microfractures | 9 |
| 246 | mini-dosage | 1 |
| 247 | minimalization | 4 |
| 248 | mis-recording | 1 |
| 249 | mismeasurement | 4 |
| 250 | mistnetting | 1 |
| 251 | mock-ups | 3 |
| 252 | mono-n-arylation | 1 |
| 253 | mono-pegylation | 1 |
| 254 | monoadministration | 4 |
| 255 | monozygosity | 3 |
| 256 | morpho-anatomy | 2 |
| 257 | mp688 | 5 |
| 258 | mrna-expression | 6 |
| 259 | multiparticulates | 2 |
| 260 | multistageness | 1 |
| 261 | n-terminal-prohormone | 1 |
| 262 | n4-nymphs | 2 |
| 263 | n6-derivatives | 1 |
| 264 | nanoheterostructures/mixtures | 1 |
| 265 | nanolizing | 1 |
| 266 | ngmi | 3 |
| 267 | nhe3-s515d | 1 |
| 268 | nighty-eight | 1 |
| 269 | nine-month-olds | 1 |
| 270 | non-consideration | 3 |
| 271 | non-culturable | 3 |
| 272 | non-neutropenia | 1 |
| 273 | non-observances | 1 |
| 274 | non-receipt | 2 |
| 275 | non-recommendation | 1 |
| 276 | non-support | 3 |
| 277 | noncoresidentiality | 1 |
| 278 | none | 8,646 |
| 279 | nonengagement | 2 |
| 280 | nonfsws | 1 |
| 281 | nonoverlap | 1 |
| 282 | nonplacement | 2 |
| 283 | nonstandardization | 2 |
| 284 | nos-dependence | 4 |
| 285 | observer-rating | 1 |
| 286 | occurrence/duration | 1 |
| 287 | osypka-electrodes | 2 |
| 288 | over-absorption | 2 |
| 289 | over-repetition | 1 |
| 290 | over-stretching | 1 |
| 291 | pan-inhibition | 2 |
| 292 | papillitis | 3 |
| 293 | parent/s | 1 |
| 294 | pc-coating | 1 |
| 295 | pentalogy | 2 |
| 296 | percpetions | 1 |
| 297 | peritonitiss | 1 |
| 298 | pharmacoprevention | 1 |
| 299 | phosphomimics | 1 |
| 300 | photocopies | 2 |
| 301 | physician-assessment | 1 |
| 302 | pif4-dependency | 1 |
| 303 | pinches | 2 |
| 304 | placebo-dp | 2 |
| 305 | placentomas | 2 |
| 306 | plain-radiography | 2 |
| 307 | police-records | 1 |
| 308 | polysomnographs | 1 |
| 309 | portents | 1 |
| 310 | post-analysis | 1 |
| 311 | practicians | 2 |
| 312 | pre-addition | 1 |
| 313 | pre-infusions | 2 |
| 314 | pre-metalation | 1 |
| 315 | predictors/correlates | 1 |
| 316 | preinhibition | 1 |
| 317 | prelicensing | 2 |
| 318 | prevention-by-detection | 1 |
| 319 | protocolization | 1 |
| 320 | pseudo-subluxation | 1 |
| 321 | pseudo-tumour | 2 |
| 322 | pumping.initiation | 1 |
| 323 | purpouse | 1 |
| 324 | pyes2.0 | 3 |
| 325 | qanun | 1 |
| 326 | radiometabolites | 1 |
| 327 | radiomethylation | 1 |
| 328 | ranges-of-motion | 1 |
| 329 | rbc-aa | 3 |
| 330 | re-supplementation | 1 |
| 331 | re-supply | 3 |
| 332 | re-suspension | 3 |
| 333 | re-ulcerations | 1 |
| 334 | reactogenicities | 1 |
| 335 | recondensation | 1 |
| 336 | reduction/suppression | 3 |
| 337 | remaking | 2 |
| 338 | resensitization | 2 |
| 339 | results-27,495 | 1 |
| 340 | results.-forty-one | 1 |
| 341 | rhi+rhuph20 | 2 |
| 342 | ricochet | 1 |
| 343 | riv/bullock | 2 |
| 344 | rnai-knockdown | 1 |
| 345 | robustification | 1 |
| 346 | rs1544210 | 1 |
| 347 | rupture/dissection | 1 |
| 348 | s'lateral | 2 |
| 349 | sacculations | 3 |
| 350 | sdspage | 1 |
| 351 | sect | 23 |
| 352 | self-predictions | 1 |
| 353 | semiquantitation | 1 |
| 354 | serials | 1 |
| 355 | seroprevalency | 1 |
| 356 | seventy-fife | 1 |
| 357 | sigma/epsilon | 1 |
| 358 | silver-coating | 4 |
| 359 | six1 | 2 |
| 360 | sixty-percent | 2 |
| 361 | smgs | 7 |
| 362 | solarization | 2 |
| 363 | sss2a | 4 |
| 364 | start-strengths | 2 |
| 365 | staurosporine/h89-sensitive | 1 |
| 366 | submariners | 3 |
| 367 | subphenotyping | 1 |
| 368 | subspecialisation | 1 |
| 369 | subterms | 1 |
| 370 | sucking-tucking | 2 |
| 371 | suzuki-coupling | 1 |
| 372 | t1-effects | 1 |
| 373 | t1-ld | 1 |
| 374 | t1=start | 1 |
| 375 | t2-ld | 1 |
| 376 | t3-ld | 1 |
| 377 | tadenan | 2 |
| 378 | tamaris | 1 |
| 379 | tape-recordings | 1 |
| 380 | tc-99m-hdp-spect/ct | 1 |
| 381 | teacorac | 2 |
| 382 | ten-year-risk | 1 |
| 383 | theaim | 2 |
| 384 | thearomaticities | 1 |
| 385 | theconcentrations | 1 |
| 386 | thermal-activation | 1 |
| 387 | thermo-acclimated | 1 |
| 388 | thermoactivity | 1 |
| 389 | theuse | 1 |
| 390 | time-to-use | 2 |
| 391 | times-series | 1 |
| 392 | tnf-α-modulation | 1 |
| 393 | toxigenesis | 2 |
| 394 | trans-stimulation | 1 |
| 395 | transcomplementation | 1 |
| 396 | transplantation/infusion | 1 |
| 397 | treatment-effects | 1 |
| 398 | triplots | 1 |
| 399 | trofozoites | 1 |
| 400 | twenty-items | 1 |
| 401 | type/side | 1 |
| 402 | ual/sal | 3 |
| 403 | uncleanliness | 3 |
| 404 | under-users | 3 |
| 405 | underinflation | 2 |
| 406 | uninducibility | 1 |
| 407 | unkindled | 1 |
| 408 | unplanned-use | 1 |
| 409 | wb-mris | 1 |
| 410 | wcg3 | 2 |
| 411 | web/mail | 4 |
| 412 | withdrawel | 1 |
| 413 | x-ray-dose | 1 |
| 414 | ~bullet~withdrawal | 1 |
| 415 | «history | 1 |
| 416 | β-cleavage | 1 |
| 417 | β1-subunit | 1 |
| 418 | ιmmunoreactivity | 1 |
| 419 | •discrimination | 1 |
| 420 | •harms | 1 |
| 421 | •meta-analysis | 1 |
| 422 | •predictors | 1 |
| 423 | ≥20/400 | 1 |
| 1 | pyes2.0 | 3 |
| 2 | glu100 | 1 |
| 3 | ≥20/400 | 1 |
| 4 | 577/1500 | 1 |
| 5 | rs1544210 | 1 |
| 6 | rhi+rhuph20 | 2 |
| 7 | lys890 | 1 |
| 8 | mic50/mic90 | 1 |
| 9 | 63·0 | 1 |
| 10 | 26,601 | 1 |
| 11 | 2005-31 | 1 |
| 12 | 10+/-2.41 | 1 |
| 13 | 28,661 | 1 |
| 14 | 90+/-0.71 | 1 |
| 15 | marop1 | 3 |
| 16 | six1 | 2 |
| 17 | 1+/-2 | 3 |
| 18 | 18+/-1.32 | 1 |
| 19 | 27,062 | 2 |
| 20 | eb172 | 2 |
| 21 | 1313±603 | 1 |
| 22 | 62/113 | 1 |
| 23 | 4,513 | 1 |
| 24 | 5783 | 1 |
| 25 | 17+/-7.93 | 1 |
| 26 | 72/93 | 1 |
| 27 | wcg3 | 2 |
| 28 | 1/5-1/4 | 1 |
| 29 | anti-cd14 | 2 |
| 30 | 35/54 | 2 |
| 31 | 11/154 | 1 |
| 32 | 180,894 | 1 |
| 33 | 3.54-/+1.95 | 1 |
| 34 | 30,495 | 1 |
| 35 | results-27,495 | 1 |
| 36 | 22,6±3,6 | 1 |
| 37 | 28,156 | 1 |
| 38 | 10,356 | 1 |
| 39 | com456 | 5 |
| 40 | 90+/-1.86 | 1 |
| 41 | 90,517 | 1 |
| 42 | b*44:27 | 2 |
| 43 | 6337 | 1 |
| 44 | 11,967 | 2 |
| 45 | 7,97±1,87 | 1 |
| 46 | 1086-1087 | 1 |
| 47 | 6,248 | 1 |
| 48 | mp688 | 5 |
| 49 | 19/49 | 2 |
| 50 | 179,149 | 1 |
| 51 | 3549 | 2 |
| 52 | met-159 | 1 |
| 53 | 4169 | 3 |
| 54 | 17,779 | 1 |
| 55 | 13,489 | 1 |
| 56 | h272a | 1 |
| 57 | sss2a | 4 |
| 58 | k256a | 1 |
| 59 | rbc-aa | 3 |
| 60 | diarrrhoea | 1 |
| 61 | encyclopaedia | 6 |
| 62 | metorrhagia | 2 |
| 63 | hyperamylaesemia | 1 |
| 64 | non-neutropenia | 1 |
| 65 | macrodontia | 3 |
| 66 | 'edema | 2 |
| 67 | chondosarcoma | 1 |
| 68 | 16b | 1 |
| 69 | antibodies-to-golimumab | 1 |
| 70 | fenobucarb | 4 |
| 71 | teacorac | 2 |
| 72 | 3.00dc | 1 |
| 73 | 3d-ctc | 1 |
| 74 | cf-htc | 4 |
| 75 | 4g/d | 4 |
| 76 | nhe3-s515d | 1 |
| 77 | devoided | 1 |
| 78 | unkindled | 1 |
| 79 | meausured | 1 |
| 80 | thermo-acclimated | 1 |
| 81 | t1-ld | 1 |
| 82 | t2-ld | 1 |
| 83 | t3-ld | 1 |
| 84 | flowerbud | 1 |
| 85 | nos-dependence | 4 |
| 86 | 'science | 2 |
| 87 | disappearence | 1 |
| 88 | 0=absence | 1 |
| 89 | 1=presence | 1 |
| 90 | 2=presence | 1 |
| 91 | co-blockade | 1 |
| 92 | type/side | 1 |
| 93 | carboxy-telopeptide | 2 |
| 94 | 'attitude | 3 |
| 95 | seventy-fife | 1 |
| 96 | sdspage | 1 |
| 97 | mini-dosage | 1 |
| 98 | β-cleavage | 1 |
| 99 | non-culturable | 3 |
| 100 | 0.44.fluoxetine | 1 |
| 101 | beta-ol-15-one | 1 |
| 102 | results.-forty-one | 1 |
| 103 | n-terminal-prohormone | 1 |
| 104 | none | 8,646 |
| 105 | barrier-type | 1 |
| 106 | ets-exposure | 3 |
| 107 | g4-mixture | 1 |
| 108 | maintenance/increase | 1 |
| 109 | x-ray-dose | 1 |
| 110 | unplanned-use | 1 |
| 111 | time-to-use | 2 |
| 112 | theuse | 1 |
| 113 | purpouse | 1 |
| 114 | staurosporine/h89-sensitive | 1 |
| 115 | erβ-positive | 1 |
| 116 | 4-hour-area-under-the-curve | 1 |
| 117 | 210.g | 1 |
| 118 | 6g/100g | 2 |
| 119 | 40g | 3 |
| 120 | 80g | 2 |
| 121 | 59±11g | 1 |
| 122 | 0.48±0.02g | 1 |
| 123 | 3-dag | 4 |
| 124 | 20.3g/kg | 1 |
| 125 | 1500mg/kg | 2 |
| 126 | 38µg/kg | 1 |
| 127 | 10-50μg/kg | 1 |
| 128 | 0.12±0.003ml/kg | 1 |
| 129 | imatinib-600mg | 1 |
| 130 | 44mg | 1 |
| 131 | 7.5tymg | 1 |
| 132 | immunoprobing | 2 |
| 133 | methylation-silencing | 1 |
| 134 | mis-recording | 1 |
| 135 | over-stretching | 1 |
| 136 | remaking | 2 |
| 137 | sucking-tucking | 2 |
| 138 | suzuki-coupling | 1 |
| 139 | fractioning | 2 |
| 140 | subphenotyping | 1 |
| 141 | bleeding/bruising | 1 |
| 142 | prelicensing | 2 |
| 143 | co-dosing | 2 |
| 144 | pc-coating | 1 |
| 145 | silver-coating | 4 |
| 146 | observer-rating | 1 |
| 147 | co-targeting | 1 |
| 148 | mistnetting | 1 |
| 149 | day-wetting | 1 |
| 150 | imunoblotting | 1 |
| 151 | degloving | 1 |
| 152 | nanolizing | 1 |
| 153 | b26arg | 6 |
| 154 | ipt-wg | 5 |
| 155 | 1-oh | 1 |
| 156 | 0.14/subject/month | 1 |
| 157 | hongbaozhai | 1 |
| 158 | ciii2/cii | 1 |
| 159 | ngmi | 3 |
| 160 | fcj/fcpj | 4 |
| 161 | insufficient/lack | 1 |
| 162 | gal/wilcock | 1 |
| 163 | riv/bullock | 2 |
| 164 | ten-year-risk | 1 |
| 165 | 4g/l | 2 |
| 166 | 8l | 15 |
| 167 | s'lateral | 2 |
| 168 | ual/sal | 3 |
| 169 | ~bullet~withdrawal | 1 |
| 170 | withdrawel | 1 |
| 171 | web/mail | 4 |
| 172 | meddiet-wl | 2 |
| 173 | dp-gram | 1 |
| 174 | theaim | 2 |
| 175 | hal2pim | 3 |
| 176 | mecanism | 1 |
| 177 | comparism | 1 |
| 178 | angioscan | 1 |
| 179 | tadenan | 2 |
| 180 | gemifloxacin/azithromycin | 3 |
| 181 | c21min | 1 |
| 182 | 2,3,7,8-tetrabromo-dibenzodioxin | 1 |
| 183 | co-provision | 1 |
| 184 | re-suspension | 3 |
| 185 | reduction/suppression | 3 |
| 186 | mrna-expression | 6 |
| 187 | cooverexpression | 1 |
| 188 | maternal-to-child-transmission | 1 |
| 189 | transplantation/infusion | 1 |
| 190 | exfusion | 1 |
| 191 | administra-tion | 1 |
| 192 | 'identification | 2 |
| 193 | robustification | 1 |
| 194 | chemo-degradation | 1 |
| 195 | non-recommendation | 1 |
| 196 | 'aggregation | 1 |
| 197 | invastigation | 1 |
| 198 | 'initiation | 1 |
| 199 | pumping.initiation | 1 |
| 200 | pre-metalation | 1 |
| 201 | hemi-ablation | 1 |
| 202 | underinflation | 2 |
| 203 | co-inoculation | 2 |
| 204 | agroinoculation | 1 |
| 205 | tnf-α-modulation | 1 |
| 206 | chemomodulation | 1 |
| 207 | 'regulation | 2 |
| 208 | de-regulation | 1 |
| 209 | catecholamine-regulation | 1 |
| 210 | il-6-stimulation | 1 |
| 211 | dc-stimulation | 4 |
| 212 | trans-stimulation | 1 |
| 213 | benzoannulation | 1 |
| 214 | mono-pegylation | 1 |
| 215 | radiomethylation | 1 |
| 216 | aminomethylation | 2 |
| 217 | mono-n-arylation | 1 |
| 218 | laboratory-confirmation | 1 |
| 219 | •discrimination | 1 |
| 220 | divorce/separation | 4 |
| 221 | consecration | 1 |
| 222 | non-consideration | 3 |
| 223 | monoadministration | 4 |
| 224 | occurrence/duration | 1 |
| 225 | subspecialisation | 1 |
| 226 | medialisation | 4 |
| 227 | devitalisation | 1 |
| 228 | humanisation | 1 |
| 229 | electro-polymerisation | 1 |
| 230 | recondensation | 1 |
| 231 | implanatation | 1 |
| 232 | co-immunprecipitation | 1 |
| 233 | semiquantitation | 1 |
| 234 | bi-transplantation | 1 |
| 235 | decementation | 4 |
| 236 | transcomplementation | 1 |
| 237 | re-supplementation | 1 |
| 238 | bioevaluation | 2 |
| 239 | thermal-activation | 1 |
| 240 | electro-activation | 1 |
| 241 | pseudo-subluxation | 1 |
| 242 | nonstandardization | 2 |
| 243 | judicialization | 1 |
| 244 | minimalization | 4 |
| 245 | lab-demineralization | 1 |
| 246 | protocolization | 1 |
| 247 | insulinization | 2 |
| 248 | chronization | 2 |
| 249 | asynchronization | 1 |
| 250 | differentiation/polarization | 1 |
| 251 | solarization | 2 |
| 252 | legitimatization | 1 |
| 253 | resensitization | 2 |
| 254 | effectivization | 1 |
| 255 | rupture/dissection | 1 |
| 256 | prevention-by-detection | 1 |
| 257 | co-deletion | 3 |
| 258 | immunodepletion | 4 |
| 259 | pan-inhibition | 2 |
| 260 | preinhibition | 1 |
| 261 | pre-addition | 1 |
| 262 | over-repetition | 1 |
| 263 | drug-prevention | 1 |
| 264 | pharmacoprevention | 1 |
| 265 | ranges-of-motion | 1 |
| 266 | over-absorption | 2 |
| 267 | eruption/noneruption | 1 |
| 268 | sigma/epsilon | 1 |
| 269 | qanun | 1 |
| 270 | rnai-knockdown | 1 |
| 271 | l-placebo | 3 |
| 272 | nonoverlap | 1 |
| 273 | placebo-dp | 2 |
| 274 | its-rflp | 1 |
| 275 | follow-op | 1 |
| 276 | ema/pma-qpcr | 2 |
| 277 | alpha-factor | 1 |
| 278 | 'rigour | 1 |
| 279 | pseudo-tumour | 2 |
| 280 | measure/s | 3 |
| 281 | parent/s | 1 |
| 282 | placentomas | 2 |
| 283 | phosphomimics | 1 |
| 284 | immunocharacteristics | 1 |
| 285 | axos-breads | 2 |
| 286 | nine-month-olds | 1 |
| 287 | police-records | 1 |
| 288 | fdaes | 1 |
| 289 | non-observances | 1 |
| 290 | 'sources | 2 |
| 291 | c-terminal-telopeptides | 2 |
| 292 | osypka-electrodes | 2 |
| 293 | demages | 1 |
| 294 | pinches | 2 |
| 295 | handsearches | 132 |
| 296 | context-studies | 1 |
| 297 | photocopies | 2 |
| 298 | times-series | 1 |
| 299 | reactogenicities | 1 |
| 300 | thearomaticities | 1 |
| 301 | 75-couples | 1 |
| 302 | -outcomes | 1 |
| 303 | f-scores | 2 |
| 304 | 1965.-spores | 1 |
| 305 | microfractures | 9 |
| 306 | nanoheterostructures/mixtures | 1 |
| 307 | predictors/correlates | 1 |
| 308 | multiparticulates | 2 |
| 309 | guesstimates | 1 |
| 310 | radiometabolites | 1 |
| 311 | trofozoites | 1 |
| 312 | n6-derivatives | 1 |
| 313 | smgs | 7 |
| 314 | tape-recordings | 1 |
| 315 | polysomnographs | 1 |
| 316 | n4-nymphs | 2 |
| 317 | start-strengths | 2 |
| 318 | tamaris | 1 |
| 319 | wb-mris | 1 |
| 320 | dermatochalasis | 4 |
| 321 | toxigenesis | 2 |
| 322 | anisonucleosis | 2 |
| 323 | •meta-analysis | 1 |
| 324 | post-analysis | 1 |
| 325 | papillitis | 3 |
| 326 | leatherbacks | 2 |
| 327 | serials | 1 |
| 328 | twenty-items | 1 |
| 329 | •harms | 1 |
| 330 | subterms | 1 |
| 331 | chest-ct-scans | 1 |
| 332 | practicians | 2 |
| 333 | maidens | 1 |
| 334 | hdl-lipoproteins | 1 |
| 335 | pre-infusions | 2 |
| 336 | sacculations | 3 |
| 337 | lipid-formulations | 1 |
| 338 | re-ulcerations | 1 |
| 339 | microaspirations | 4 |
| 340 | theconcentrations | 1 |
| 341 | coimmunoprecipitations | 3 |
| 342 | immunolocalizations | 1 |
| 343 | functionalizations | 2 |
| 344 | self-predictions | 1 |
| 345 | percpetions | 1 |
| 346 | lnterventions | 1 |
| 347 | gsos | 1 |
| 348 | 3-egfps | 2 |
| 349 | mock-ups | 3 |
| 350 | altars | 1 |
| 351 | mcrs | 1 |
| 352 | cases-folders | 1 |
| 353 | submariners | 3 |
| 354 | under-users | 3 |
| 355 | emperors | 3 |
| 356 | •predictors | 1 |
| 357 | multistageness | 1 |
| 358 | uncleanliness | 3 |
| 359 | peritonitiss | 1 |
| 360 | 'impacts | 1 |
| 361 | 'effects | 2 |
| 362 | t1-effects | 1 |
| 363 | long-term-effects | 1 |
| 364 | treatment-effects | 1 |
| 365 | homomutants | 1 |
| 366 | portents | 1 |
| 367 | triplots | 1 |
| 368 | boxplots | 1 |
| 369 | nonfsws | 1 |
| 370 | tc-99m-hdp-spect/ct | 1 |
| 371 | sect | 23 |
| 372 | ricochet | 1 |
| 373 | nighty-eight | 1 |
| 374 | β1-subunit | 1 |
| 375 | impairmant | 1 |
| 376 | eighty-percent | 1 |
| 377 | sixty-percent | 2 |
| 378 | nonplacement | 2 |
| 379 | nonengagement | 2 |
| 380 | mismeasurement | 4 |
| 381 | establisment | 1 |
| 382 | physician-assessment | 1 |
| 383 | destot | 4 |
| 384 | non-receipt | 2 |
| 385 | t1=start | 1 |
| 386 | non-support | 3 |
| 387 | dna-test | 3 |
| 388 | behavior/out | 1 |
| 389 | 15x | 1 |
| 390 | 'legitimacy | 1 |
| 391 | pif4-dependency | 1 |
| 392 | co-deficiency | 1 |
| 393 | seroprevalency | 1 |
| 394 | 'frequency | 7 |
| 395 | pentalogy | 2 |
| 396 | plain-radiography | 2 |
| 397 | biogenesis/assembly | 2 |
| 398 | gamma-family | 1 |
| 399 | re-supply | 3 |
| 400 | disfluently | 1 |
| 401 | morpho-anatomy | 2 |
| 402 | hepaticogastrotomy | 1 |
| 403 | adultery | 2 |
| 404 | «history | 1 |
| 405 | microdensitometry | 1 |
| 406 | accuracy/specificity | 1 |
| 407 | noncoresidentiality | 1 |
| 408 | marriageability | 1 |
| 409 | drugability | 1 |
| 410 | cytoviability | 1 |
| 411 | bioavalability | 1 |
| 412 | cross-transferability | 3 |
| 413 | uninducibility | 1 |
| 414 | bio-compatibility | 1 |
| 415 | availablility | 1 |
| 416 | 'sincerity | 1 |
| 417 | immunodensity | 1 |
| 418 | monozygosity | 3 |
| 419 | ιmmunoreactivity | 1 |
| 420 | thermoactivity | 1 |
| 421 | feasibilty | 1 |
| 422 | cellonex™ | 3 |
| 423 | 109.7° | 2 |